Analysis of Mutations in Fibroblast Growth Factor (FGF) and a Pathogenic Mutation in FGF Receptor (FGFR) Provides Direct Evidence for the Symmetric Two-End Model for FGFR Dimerization

REFERENCES

• Anderson, J., H. D. Burns, P. Enriquez-Harris, A. O. Wilkie, and J. K. Heath. 1998. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum. Mol. Genet. 7:1475–1483.
   PubMed Web of Science ®Google Scholar
• Borchers, C., and K. B. Tomer. 1999. Characterization of the noncovalent complex of human immunodeficiency virus glycoprotein 120 with its cellular receptor CD4 by matrix-assisted laser desorption/ionization mass spectrometry. Biochemistry 38:11734–11740.
   PubMed Web of Science ®Google Scholar
• Brunger, A. T., P. D. Adams, G. M. Clore, W. L. DeLano, P. Gros, R. W. Grosse-Kunstleve, J. S. Jiang, J. Kuszewski, M. Nilges, N. S. Pannu, R. J. Read, L. M. Rice, T. Simonson, and G. L. Warren. 1998. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 54:905–921.
   PubMed Web of Science ®Google Scholar
• Cadene, M., and B. T. Chait. 2000. A robust, detergent-friendly method for mass spectrometric analysis of integral membrane proteins. Anal. Chem. 72:5655–5658.
   PubMed Web of Science ®Google Scholar
• Harmer, N. J., L. Pellegrini, D. Chirgadze, J. Fernandez-Recio, and T. L. Blundell. 2004. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 43:629–640.
   PubMedGoogle Scholar
• Ibrahimi, O. A., A. V. Eliseenkova, A. N. Plotnikov, K. Yu, D. M. Ornitz, and M. Mohammadi. 2001. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc. Natl. Acad. Sci. USA 98:7182–7187.
   PubMed Web of Science ®Google Scholar
• Ibrahimi, O. A., F. Zhang, A. V. Eliseenkova, N. Itoh, R. J. Linhardt, and M. Mohammadi. 2004. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum. Mol. Genet. 13:2313–2324.
   PubMed Web of Science ®Google Scholar
• Ibrahimi, O. A., F. Zhang, A. V. Eliseenkova, R. J. Linhardt, and M. Mohammadi. 2004. Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum. Mol. Genet. 13:69–78.
   PubMed Web of Science ®Google Scholar
• Ibrahimi, O. A., F. Zhang, S. C. Lang Hrstka, M. Mohammadi, and R. J. Linhardt. 2004. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry 43:4724–4730.
   PubMedGoogle Scholar
• Igarashi, M., P. W. Finch, and S. A. Aaronson. 1998. Characterization of recombinant human fibroblast growth factor (FGF)-10 reveals functional similarities with keratinocyte growth factor (FGF-7). J. Biol. Chem. 273:13230–13235.
   PubMedGoogle Scholar
• Jabs, E. W. 2002. Genetic etiologies of craniosynostosis, p. 125–146. In M. K. Mooney and M. I. Siegel (ed.), Understanding craniofacial anomalies: the etiopathogenesis of craniosynostoses and facial clefting. Wiley-Liss, New York, N.Y.
   Google Scholar
• Jaye, M., J. Schlessinger, and C. A. Dionne. 1992. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim. Biophys. Acta 1135:185–199.
   PubMed Web of Science ®Google Scholar
• Jespersen, S., W. M. Niessen, U. R. Tjaden, and J. van der Greef. 1998. Basic matrices in the analysis of non-covalent complexes by matrix-assisted laser desorption/ionization mass spectrometry. J. Mass Spectrom. 33:1088–1093.
   PubMedGoogle Scholar
• Johnson, D. E., L. T. Williams, A. Gritli-Linde, P. Lewis, A. P. McMahon, and A. Linde. 1993. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 60:1–41.
   PubMed Web of Science ®Google Scholar
• Jones, T. A., J. Y. Zou, S. W. Cowan, and G. Kjeldgaard. 1991. Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47:110–119.
   PubMed Web of Science ®Google Scholar
• Kan, S. H., N. Elanko, D. Johnson, L. Cornejo-Roldan, J. Cook, E. W. Reich, S. Tomkins, A. Verloes, S. R. Twigg, S. Rannan-Eliya, D. M. McDonald-McGinn, E. H. Zackai, S. A. Wall, M. Muenke, and A. O. Wilkie. 2002. Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. Am. J. Hum. Genet. 70:472–486.
   PubMedGoogle Scholar
• Martin, G. R. 1998. The roles of FGFs in the early development of vertebrate limbs. Genes Dev. 12:1571–1586.
   PubMed Web of Science ®Google Scholar
• Miki, T., D. P. Bottaro, T. P. Fleming, C. L. Smith, W. H. Burgess, A. M. Chan, and S. A. Aaronson. 1992. Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc. Natl. Acad. Sci. USA 89:246–250.
   PubMed Web of Science ®Google Scholar
• Muenke, M., and A. O. Wilkie. 2001. Craniosynostosis syndromes, p. 6117–6146. In C. R. Scriver, A. L. Beaudet, D. Valle, W. S. Sly, B. Childs, K. Kinzler, and B. Vogelstein (ed.), The metabolic and molecular bases of inherited disease, vol. IV. McGraw-Hill, New York, N.Y.
   Google Scholar
• Olsen, S. K., O. A. Ibrahimi, A. Raucci, F. Zhang, A. V. Eliseenkova, A. Yayon, C. Basilico, R. J. Linhardt, J. Schlessinger, and M. Mohammadi. 2004. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc. Natl. Acad. Sci. USA 101:935–940.
   PubMed Web of Science ®Google Scholar
• Ornitz, D. M., and N. Itoh. 2001. Fibroblast growth factors. Genome Biol. 2:1–12.
   Web of Science ®Google Scholar
• Ornitz, D. M., A. Yayon, J. G. Flanagan, C. M. Svahn, E. Levi, and P. Leder. 1992. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol. Cell. Biol. 12:240–247.
   PubMed Web of Science ®Google Scholar
• Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307–326.
   PubMed Web of Science ®Google Scholar
• Pellegrini, L., D. F. Burke, F. von Delft, B. Mulloy, and T. L. Blundell. 2000. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407:1029–1034.
   PubMed Web of Science ®Google Scholar
• Pfeiffer, R. A. 1964. Dominant erbliche Akrocephalosyndaktylie. Z. Kinderheilk. 90:301.
   PubMedGoogle Scholar
• Plotnikov, A. N., S. R. Hubbard, J. Schlessinger, and M. Mohammadi. 2000. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101:413–424.
   PubMed Web of Science ®Google Scholar
• Plotnikov, A. N., J. Schlessinger, S. R. Hubbard, and M. Mohammadi. 1999. Structural basis for FGF receptor dimerization and activation. Cell 98:641–650.
   PubMed Web of Science ®Google Scholar
• Rapraeger, A. C., A. Krufka, and B. B. Olwin. 1991. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252:1705–1708.
   PubMed Web of Science ®Google Scholar
• Reimer, U., G. Scherer, M. Drewello, S. Kruber, M. Schutkowski, and G. Fischer. 1998. Side-chain effects on peptidyl-prolyl cis/trans isomerisation. J. Mol. Biol. 279:449–460.
   PubMed Web of Science ®Google Scholar
• Schlessinger, J., A. N. Plotnikov, O. A. Ibrahimi, A. V. Eliseenkova, B. K. Yeh, A. Yayon, R. J. Linhardt, and M. Mohammadi. 2000. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6:743–750.
   PubMed Web of Science ®Google Scholar
• Shimada, T., S. Mizutani, T. Muto, T. Yoneya, R. Hino, S. Takeda, Y. Takeuchi, T. Fujita, S. Fukumoto, and T. Yamashita. 2001. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. USA 98:6500–6505.
   PubMed Web of Science ®Google Scholar
• Stauber, D. J., A. D. DiGabriele, and W. A. Hendrickson. 2000. Structural interactions of fibroblast growth factor receptor with its ligands. Proc. Natl. Acad. Sci. USA 97:49–54.
   PubMed Web of Science ®Google Scholar
• Wang, F., M. Kan, G. Yan, J. Xu, and W. L. McKeehan. 1995. Alternately spliced NH2-terminal immunoglobulin-like loop I in the ectodomain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1. J. Biol. Chem. 270:10231–10235.
   PubMed Web of Science ®Google Scholar
• White, K. E., K. B. Jonsson, G. Carn, G. Hampson, T. D. Spector, M. Mannstadt, B. Lorenz-Depiereux, A. Miyauchi, I. M. Yang, O. Ljunggren, T. Meitinger, T. M. Strom, H. Juppner, and M. J. Econs. 2001. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J. Clin. Endocrinol. Metab. 86:497–500.
   PubMedGoogle Scholar
• Wilkie, A. O., S. F. Slaney, M. Oldridge, M. D. Poole, G. J. Ashworth, A. D. Hockley, R. D. Hayward, D. J. David, L. J. Pulleyn, P. Rutland, et al. 1995. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat. Genet. 9:165–172.
   PubMed Web of Science ®Google Scholar
• Wilkin, D. J., J. T. Hecht, and C. A. Francomano. 2001. Achondroplasia and pseudoachondroplasia, p. 5379–5395. In C. R. Scriver, A. L. Beaudet, D. Valle, W. S. Sly, B. Childs, K. Kinzler, and B. Vogelstein (ed.), The metabolic and molecular bases of inherited disease, vol. IV. McGraw-Hill, New York, N.Y.
   Google Scholar
• Yayon, A., M. Klagsbrun, J. D. Esko, P. Leder, and D. M. Ornitz. 1991. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841–848.
   PubMed Web of Science ®Google Scholar
• Yayon, A., Y. Zimmer, G. H. Shen, A. Avivi, Y. Yarden, and D. Givol. 1992. A confined variable region confers ligand specificity on fibroblast growth factor receptors: implications for the origin of the immunoglobulin fold. EMBO J. 11:1885–1890.
   PubMedGoogle Scholar
• Yeh, B. K., M. Igarashi, A. V. Eliseenkova, A. N. Plotnikov, I. Sher, D. Ron, S. A. Aaronson, and M. Mohammadi. 2003. Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc. Natl. Acad. Sci. USA 100:2266–2271.
   PubMed Web of Science ®Google Scholar
• Zhang, F., M. Fath, R. Marks, and R. J. Linhardt. 2002. A highly stable covalent conjugated heparin biochip for heparin-protein interaction studies. Anal. Biochem. 304:271–273.
   PubMed Web of Science ®Google Scholar